Ergoteles’s Kalaris Therapeutics KLRS Stock Holding History

Ergoteles’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-511	Closed	-$60.3K	–	1836
2022 Q4	$60.3K	Buy	+511	New	+$86.7K	﹤0.01%	1278
2022 Q3	–	Sell	-1,235	Closed	-$111K	–	2065
2022 Q2	$111K	Buy	+1,235	New	+$129K	﹤0.01%	1475

Other funds holding KLRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Ergoteles's KLRS Position: Q1 2023 in Review

Ergoteles sold out of Kalaris Therapeutics (KLRS) in Q1 2023, closing a stake of 511 shares — an estimated $60.3K sold.

Ergoteles first reported a position in KLRS in Q2 2022 and held it in 2 quarters. The position peaked at $111K in Q2 2022. 89 funds tracked by Wall St. Rank hold KLRS as of Q1 2023.

Ergoteles reported no remaining Kalaris Therapeutics position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 511 Kalaris Therapeutics shares in Q1 2023, an estimated $60.3K.
Ergoteles first reported a position in Kalaris Therapeutics in Q2 2022 and held it in 2 quarters.
Ergoteles's Kalaris Therapeutics position peaked at $111K in Q2 2022.
89 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.